18F-FES and 18F-FDG PET/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4/6 kinase inhibitors with endocrine treatment
ConclusionsThis study shows that FDG and FES PET imaging may serve as valuable tools for patient selection in the context of CDK4/6 inhibitor therapy combined with endocrine treatment, and have the potential to function as prognostic biomarkers.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | CT Scan | Endocrine Therapy | Nuclear Medicine | PET Scan | Study